The acetaminophen-derived bioactive N-acylphenolamine AM404 inhibits NFAT by targeting nuclear regulatory events

Biochemical Pharmacology

Volumn 73, Issue 7, 2007, Pages 1013-1023

  Caballero, Francisco J ^a   Navarrete, Carmen M ^a   Hess, Sandra ^b   Fiebich, Bernd L ^b   Appendino, Giovanni ^c   Macho, Antonio ^a   Muñoz, Eduardo ^a   Sancho, Rocío ^a  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Lipid mediators; Signal transduction; T cells

Indexed keywords

AMN 404; ANANDAMIDE; CALCIUM; CANNABINOID 1 RECEPTOR; CD3 ANTIGEN; DRUG METABOLITE; ENDOCANNABINOID; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; LIGAND; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; PARACETAMOL; PROTEIN NFAT1; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR GAL4; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ARTICLE; CALCIUM MOBILIZATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ACETAMINOPHEN; ARACHIDONIC ACIDS; HUMANS; JURKAT CELLS; NFATC TRANSCRIPTION FACTORS; NUCLEAR PROTEINS; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC;

EID: 33847169354     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.12.001     Document Type: Article

References (63)

1. Green K., Drvota V., and Vesterqvist O. Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol). Prostaglandins 37 3 (1989) 311-315
2. Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., and Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96 13 (1999) 7563-7568
3. Fiebich B.L., Lieb K., Hull M., Aicher B., van Ryn J., Pairet M., et al. Effects of caffeine and paracetamol alone or in combination with acetylsalicylic acid on prostaglandin E(2) synthesis in rat microglial cells. Neuropharmacology 39 11 (2000) 2205-2213
4. Chandrasekharan N.V., Dai H., Roos K.L., Evanson N.K., Tomsik J., Elton T.S., et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99 21 (2002) 13926-13931
5. Kis B., Snipes J.A., and Busija D.W. Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties. J Pharmacol Exp Ther 315 1 (2005) 1-7
6. Ueno K., Yamaura K., Nakamura T., Satoh T., and Yano S. Acetaminophen-induced immunosuppression associated with hepatotoxicity in mice. Res Commun Mol Pathol Pharmacol 108 3-4 (2000) 237-251
7. Hogestatt E.D., Jonsson B.A., Ermund A., Andersson D.A., Bjork H., Alexander J.P., et al. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem 280 36 (2005) 31405-31412
8. Ottani A., Leone S., Sandrini M., Ferrari A., and Bertolini A. The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. Eur J Pharmacol 531 1-3 (2006) 280-281
9. Di Marzo V., Bisogno T., and De Petrocellis L. Endocannabinoids: new targets for drug development. Curr Pharm Des 6 13 (2000) 1361-1380
10. Rice A.S., Farquhar-Smith W.P., and Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 66 2-3 (2002) 243-256
11. Iversen L., and Chapman V. Cannabinoids: a real prospect for pain relief?. Curr Opin Pharmacol 2 1 (2002) 50-55
12. Wahl P., Foged C., Tullin S., and Thomsen C. Iodo-resiniferatoxin, a new potent vanilloid receptor antagonist. Mol Pharmacol 59 1 (2001) 9-15
13. Appendino G., Minassi A., Morello A.S., De Petrocellis L., and Di Marzo V. N-Acylvanillamides: development of an expeditious synthesis and discovery of new acyl templates for powerful activation of the vanilloid receptor. J Med Chem 45 17 (2002) 3739-3745
14. Appendino G., Harrison S., De Petrocellis L., Daddario N., Bianchi F., Schiano Moriello A., et al. Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists. Br J Pharmacol 139 8 (2003) 1417-1424
15. Bisogno T., De Petrocellis L., and Di Marzo V. Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr Pharm Des 8 7 (2002) 533-547
16. Hillard C.J., and Jarrahian A. The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem Phys Lipids 108 1-2 (2000) 123-134
17. De Petrocellis L., Cascio M.G., and Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 141 5 (2004) 765-774
18. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 6743 (1999) 452-457
19. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., and Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277 5329 (1997) 1094-1097
20. Fegley D., Gaetani S., Duranti A., Tontini A., Mor M., Tarzia G., et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313 1 (2005) 352-358
21. Moore S.A., Nomikos G.G., Dickason-Chesterfield A.K., Schober D.A., Schaus J.M., Ying B.P., et al. Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc Natl Acad Sci USA 102 49 (2005) 17852-17857
22. La Rana G., Russo R., Campolongo P., Bortolato M., Mangieri R.A., Cuomo V., et al. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. J Pharmacol Exp Ther 317 3 (2006) 1365-1371
23. Rawls S.M., Ding Z., and Cowan A. Role of TRPV1 and cannabinoid CB(1) receptors in AM 404-evoked hypothermia in rats. Pharmacol Biochem Behav (2006)
24. Sancho R., De La Vega L., Appendino G., Di Marzo V., Macho A., and Munoz E. The CB1/VR1 agonist arvanil induces apoptosis through an FADD/caspase-8-dependent pathway. Br J Pharmacol 140 6 (2003) 1035-1044
25. Sancho R., Calzado M.A., Di Marzo V., Appendino G., and Munoz E. Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. Mol Pharmacol 63 2 (2003) 429-438
26. Rockwell C.E., Snider N.T., Thompson J.T., Vanden Heuvel J.P., and Kaminski N.E. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator activated receptor {gamma} independently of cannabinoid receptors 1 and 2. Mol Pharmacol (2006)
27. Sancho R., Macho A., de La Vega L., Calzado M.A., Fiebich B.L., Appendino G., et al. Immunosuppressive activity of endovanilloids: N-arachidonoyl-dopamine inhibits activation of the NF-kappa B, NFAT, and activator protein 1 signaling pathways. J Immunol 172 4 (2004) 2341-2351
28. Marquez N., De Petrocellis L., Caballero F.J., Macho A., Schiano-Moriello A., Minassi A., et al. Iodinated N-acylvanillamines: potential "multiple-target" anti-inflammatory agents acting via the inhibition of T-cell activation and antagonism at vanilloid TRPV1 channels. Mol Pharmacol 69 4 (2006) 1373-1382
29. Crabtree G.R., and Clipstone N.A. Signal transmission between the plasma membrane and nucleus of T lymphocytes. Annu Rev Biochem 63 (1994) 1045-1083
30. Lewis R.S. Calcium signaling mechanisms in T lymphocytes. Annu Rev Immunol 19 (2001) 497-521
31. Rao A., Luo C., and Hogan P.G. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 15 (1997) 707-747
32. Hogan P.G., Chen L., Nardone J., and Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 17 18 (2003) 2205-2232
33. Macian F., Lopez-Rodriguez C., and Rao A. Partners in transcription: NFAT and AP-1. Oncogene 20 19 (2001) 2476-2489
34. Weil R., and Israel A. Deciphering the pathway from the TCR to NF-kappaB. Cell Death Differ 13 5 (2006) 826-833
35. Durand D.B., Shaw J.P., Bush M.R., Replogle R.E., Belagaje R., and Crabtree G.R. Characterization of antigen receptor response elements within the interleukin-2 enhancer. Mol Cell Biol 8 4 (1988) 1715-1724
36. Rhoades K.L., Golub S.H., and Economou J.S. The regulation of the human tumor necrosis factor alpha promoter region in macrophage, T cell, and B cell lines. J Biol Chem 267 31 (1992) 22102-22107
37. Yano O., Kanellopoulos J., Kieran M., Le Bail O., Israel A., and Kourilsky P. Purification of KBF1, a common factor binding to both H-2 and beta 2-microglobulin enhancers. EMBO J 6 11 (1987) 3317-3324
38. Luo C., Burgeon E., and Rao A. Mechanisms of transactivation by nuclear factor of activated T cells-1. J Exp Med 184 1 (1996) 141-147
39. Sancho R., de la Vega L., Macho A., Appendino G., Di Marzo V., and Munoz E. Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. J Immunol 175 6 (2005) 3990-3999
40. English D., and Andersen B.R. Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. J Immunol Meth 5 3 (1974) 249-252
41. Fegley D., Kathuria S., Mercier R., Li C., Goutopoulos A., Makriyannis A., et al. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1 172. Proc Natl Acad Sci USA 101 23 (2004) 8756-8761
42. Michael B., Nair A.M., Hiraragi H., Shen L., Feuer G., Boris-Lawrie K., et al. Human T lymphotropic virus type-1 p30II alters cellular gene expression to selectively enhance signaling pathways that activate T lymphocytes. Retrovirology 1 1 (2004) 39
43. Im S.H., and Rao A. Activation and deactivation of gene expression by Ca2+/calcineurin-NFAT-mediated signaling. Mol Cells 18 (2004) 1-9
44. Bauer J., Rauschka H., and Lassmann H. Inflammation in the nervous system: the human perspective. Glia 36 2 (2001) 235-243
45. Pender M.P., and Wolfe N.P. Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects. Intern Med J 32 11 (2002) 554-563
46. Di Marzo V., Bifulco M., and De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3 (2004) 771-784
47. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Makriyannis A., et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15 (2001) 300-302
48. Cabranes A., Venderova K., de Lago E., Fezza F., Sanchez A., Mestre L., et al. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol Dis 20 2 (2005) 207-217
49. McKallip R.J., Lombard C., Fisher M., Martin B.R., Ryu S., Grant S., et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100 2 (2002) 627-634
50. Yang X.Y., Wang L.H., Chen T., Hodge D.R., Resau J.H., DaSilva L., et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 275 7 (2000) 4541-4544
51. Chung S.W., Kang B.Y., and Kim T.S. Inhibition of interleukin-4 production in CD4+ T cells by peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: involvement of physical association between PPAR-gamma and the nuclear factor of activated T cells transcription factor. Mol Pharmacol 64 5 (2003) 1169-1179
52. Stillman D.J., Sivertsen A.L., Zentner P.G., and Geiduschek E.P. Correlations between transcription of a yeast tRNA gene and transcription factor-DNA interactions. J Biol Chem 259 12 (1984) 7955-7962
53. Okamura H., Aramburu J., Garcia-Rodriguez C., Viola J.P., Raghavan A., Tahiliani M., et al. Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. Mol Cell 6 3 (2000) 539-550
54. San-Antonio B., Iniguez M.A., and Fresno M. Protein kinase Czeta phosphorylates nuclear factor of activated T cells and regulates its transactivating activity. J Biol Chem 277 30 (2002) 27073-27080
55. de Gregorio R., Iniguez M.A., Fresno M., and Alemany S. Cot kinase induces cyclooxygenase-2 expression in T cells through activation of the nuclear factor of activated T cells. J Biol Chem 276 29 (2001) 27003-27009
56. Graef I.A., Chen F., and Crabtree G.R. NFAT signaling in vertebrate development. Curr Opin Genet Dev 11 5 (2001) 505-512
57. Crabtree G.R., and Olson E.N. NFAT signaling: choreographing the social lives of cells. Cell 109 Suppl (2002) S67-S79
58. Jayanthi S., Deng X., Ladenheim B., McCoy M.T., Cluster A., Cai N.S., et al. Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis. Proc Natl Acad Sci USA 102 3 (2005) 868-873
59. Canellada A., Cano E., Sanchez-Ruiloba L., Zafra F., and Redondo J.M. Calcium-dependent expression of TNF-alpha in neural cells is mediated by the calcineurin/NFAT pathway. Mol Cell Neurosci 31 4 (2006) 692-701
60. Golan H., Levav T., Mendelsohn A., and Huleihel M. Involvement of tumor necrosis factor alpha in hippocampal development and function. Cereb Cortex 14 1 (2004) 97-105
61. Downen M., Amaral T.D., Hua L.L., Zhao M.L., and Lee S.C. Neuronal death in cytokine- activated primary human brain cell culture: role of tumor necrosis factor-alpha. Glia 28 2 (1999) 114-127
62. Ignatowski T.A., Covey W.C., Knight P.R., Severin C.M., Nickola T.J., and Spengler R.N. Brain-derived TNFalpha mediates neuropathic pain. Brain Res 841 1-2 (1999) 70-77
63. Covey W.C., Ignatowski T.A., Knight P.R., and Spengler R.N. Brain-derived TNFalpha: involvement in neuroplastic changes implicated in the conscious perception of persistent pain. Brain Res 859 1 (2000) 113-122